Cutler Group LP Zymeworks Inc. Transaction History

Cutler Group LP

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 04, 2022	SELL	$4.82 - $7.7 $1,446 - $2,310	-300 Reduced 9.68%	2,800 $14,000
Q1 2022 Apr 14, 2022	BUY	$6.0 - $16.98 $948 - $2,682	158 Added 5.37%	3,100 $20,000
Q4 2021 Jan 18, 2022	SELL	$15.19 - $29.33 $53,468 - $103,241	-3,520 Reduced 54.47%	2,942 $48,000
Q3 2021 Oct 26, 2021	BUY	$27.35 - $37.28 $51,965 - $70,832	1,900 Added 41.65%	6,462 $187,000
Q1 2021 Apr 26, 2021	BUY	$29.83 - $56.81 $79,407 - $151,228	2,662 Added 140.11%	4,562 $144,000
Q1 2020 May 07, 2020	SELL	$24.28 - $49.8 $9,712 - $19,920	-400 Reduced 17.39%	1,900 $67,000
Q3 2019 Oct 28, 2019	BUY	$22.78 - $29.08 $47,838 - $61,068	2,100 Added 1050.0%	2,300 $57,000
Q2 2019 Aug 09, 2019	BUY	$15.0 - $22.49 $3,000 - $4,498	200 New	200 $4,000

296K

Ticker ZYME
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 61,694,400
Market Cap $906M
Description
Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas...

Get notified when there are updates to the investment portfolio of Cutler Group LP, based on Form 13F filings with the SEC.

Stay updated on Cutler Group LP with notifications on news.